Results 161 to 170 of about 987,468 (263)

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) caused by niraparib: a novel antineoplastic agent. [PDF]

Allergy Asthma Clin Immunol
Vázquez-Barrera I, Juárez-Guerrero A, Cuevas-Bravo C, Perez-Ezquerra PR, Noguerado-Mellado B.   +4 more
europepmc   +1 more source

Assessment of Skin in Patients With Systemic Sclerosis Using High‐Frequency Ultrasound and Shear Wave Elastography: A Comparative Study With Histology, Molecular, and Clinical Parameters

Arthritis Care &Research, EarlyView.
Objective Ultrasound (US) has been proposed as a potential tool for assessing skin fibrosis in systemic sclerosis (SSc). However, a large‐scale comparison of US‐based assessment with histologic markers of skin fibrosis has not been reported. We evaluated US‐based skin assessments for their face validity (differentiation between involved SSc and healthy
Ruhani Desai, Filemon Tan, Minghua Wu, Jeffery L. Browning, Samuel Theodore, Meng Zhang, Brian Skaug, Harshdeep Singh Chawla, Manmohan Singh, Salavat Aglyamov, Kirill V. Larin, Maureen Mayes, Shervin Assassi   +12 more
wiley   +1 more source

An infant with drug reaction with eosinophilia and systemic symptoms caused by phenobarbital and amoxicillin: A case report. [PDF]

Medicine (Baltimore)
Matsumoto Y, Fujita M, Inuo C, Inuo C.
europepmc   +1 more source

The drug reaction problem

The American Journal of Digestive Diseases, 1967
H J, Tumen, J V, Carbone, A I, Mendeloff, F, Schaffner, H J, Zimmerman   +4 more
openaire   +3 more sources

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

Arthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti, Inmaculada C. Penadés, Irina Nikishina, Ivan Foeldvari, Alberto J. Spindler, Anna Kozlova, Nadina Rubio‐Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V. Cornejo, Katherine Marzan, Nancy Liu, Christine Xu, Stephen DiMartino, Angeliki Giannelou, Fei Cao‐Ghoul, Bolanle Akinlade, Lydie Baret‐Cormel   +19 more
wiley   +1 more source

An e-Reporting Tool for Facilitating Submission of Veterinary Adverse Drug Reaction Reports. [PDF]

J Vet Intern Med
Davies H, Smyth S, Pinchbeck G, Pirmohamed M, Savory R, Noble PJ, Killick D.   +6 more
europepmc   +1 more source

Validation of a Genetic Risk Score Combined With Clinical Variables for Predicting Pulmonary Fibrosis in Early Rheumatoid Arthritis

Arthritis Care &Research, EarlyView.
Objective Pulmonary fibrosis (PF) is a severe extra‐articular manifestation of rheumatoid arthritis (RA). This study aimed to externally validate a genetic risk score (GRS) and a combined risk score (CRS) for predicting the risk of RA‐associated PF in an independent cohort of patients with early RA.
Mikael Brink, Austin Wheeler, Bryant R. England, Solbritt Rantapää‐Dahlqvist   +3 more
wiley   +1 more source

Toxic epidermal necrolysis-like linear IgA bullous dermatosis as a manifestation of multiple drug hypersensitivity in the setting of drug reaction with eosinophilia and systemic symptoms

JAAD Case Reports
Scott Stratman, MD, MPH, Lisa Zhou, MD, Randie H. Kim, MD, Robert G. Phelps, MD, Jacob Glickman, MD, Daniela Mikhaylov, MD, Jianni Wu, MD, Nour El-Kashlan, MD, Ryan Rivera-Oyola, MD, Jonas A. Adalsteinsson, MD, PhD, Melissa A. Levoska, MD, Nicholas Gulati, MD, PhD   +11 more
doaj   +1 more source

Possible drug reaction with eosinophilia and systemic symptoms after spironolactone therapy for clinical hyperandrogenism: a case report. [PDF]

F S Rep
Hoang S, Strom D, Brennan KM.
europepmc   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, EarlyView.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators   +14 more
wiley   +1 more source